TABLE 1

Demographics and clinical neuropathy evaluation in control subjects and diabetic patients

Control subjectsNo neuropathyMildModerateSevere
n1510181511
Age (years)55.0 ± 4.7853.5 ± 3.2358.6 ± 3.0757.5 ± 2.7961.9 ± 1.89
Duration (years)016.7 ± 4.4418.4 ± 2.6425.2 ± 3.2820.4 ± 3.41
A1C (%)7.16 ± 0.407.85 ± 0.388.30 ± 0.417.88 ± 0.27
Type 1/type 23/76/125/102/9
Sex (male/female)*6/96/415/311/410/1§
SNOL (ms)2.43 ± 0.122.63 ± 0.143.03 ± 0.13§3.66 ± 0.483.03 ± 0.36
SNAP (μV)20.25 ± 3.7614.44 ± 2.365.74 ± 0.79§5.65 ± 1.19§2.65 ± 0.76§
SNCV (m/s)46.52 ± 1.8742.99 ± 1.4241.20 ± 1.2838.19 ± 2.03§35.18 ± 2.14§
PNOL(ms)4.09 ± 0.284.72 ± 0.314.62 ± 0.185.42 ± 0.27§6.41 ± 0.88
PNAP (mV)4.27 ± 0.644.26 ± 0.592.91 ± 0.431.54 ± 0.22§1.10 ± 0.75§
PNCV (m/s)45.71 ± 0.9944.15 ± 0.7940.82 ± 0.84§36.88 ± 1.41§32.37 ± 2.48§
PNFL (ms)47.36 ± 1.5853.26 ± 1.8257.43 ± 1.80§57.07 ± 2.17§63.37 ± 5.73§
TNOL (ms)4.76 ± 0.235.11 ± 0.425.67 ± 0.226.89 ± 0.43§8.29 ± 0.62§
TNAP (mV)8.70 ± 1.026.00 ± 0.724.82 ± 0.57§3.46 ± 0.99§0.83 ± 0.24§
TNCV (m/s)45.94 ± 0.9840.24 ± 1.31§38.67 ± 0.87§36.06 ± 0.78§31.18 ± 3.82§
TNFL (ms)48.59 ± 1.2155.86 ± 1.9557.73 ± 1.85§58.94 ± 2.16§72.23 ± 4.72§
CDT (percentile)66.90 ± 8.9974.22 ± 7.1296.67 ± 0.5998.00 ± 0.91
HP-VAS 0.5 (percentile)*41.38 ± 8.8734.06 ± 8.4952.20 ± 9.6881.20 ± 11.20
HP-VAS 5.0 (percentile)*46.13 ± 13.1934.67 ± 7.8748.33 ± 9.2375.80 ± 9.40
HP-VAS 0.5–5.0 (percentile)55.00 ± 11.6240.00 ± 7.8152.85 ± 9.1944.17 ± 18.10
DB-HRV (percentile)82.88 ± 4.9734.00 ± 7.9114.00 ± 5.2614.38 ± 8.67
  • Data are means ± SE for age, duration of diabetes, A1C, and measures of electrophysiology and QSTs in diabetic patients and control subjects. Statistically significant difference using ANOVA:

  • * P < 0.05;

  • P < 0.01;

  • P < 0.001.

  • § Post hoc results significantly different from control subjects.

  • Post hoc results significantly different from the group with no neuropathy.

  • Post hoc results significantly different from the group with mild neuropathy.